MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
*Funding: Surgery_Surgical Technology, Minimally Invasive & Operating Room of the Future (ORF)
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
ARCH Venture Partners - (#8 Healthcare Investor 2013) WBT
Finance & Acquisitions: Arch Ventures
*Portfolio Companies: Arch Ventures
Sana Biotechnology, Inc. (NASDAQ: SANA)*
Organization & Developments: Sana Biotech
Parents
Sana Biotechnology, Inc. (NASDAQ: SANA)*
Children
*Sana was founded to create a platform to develop cell engineering technologies, for both in vivo and ex vivo therapies
1. Sana Biotechnology
2020: Giving highly funded but secretive Moderna a run for its money, Juno-lite Sana raises $700M
2021: Investors in the firm have invested at least $853 million and include ARCH Venture Partners, Flagship Pioneering, CPP Investment Board and F-Prime Fund.
2022: Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies – GeekWire
2023: Breakthrough research could bring stem cell therapy to the masses_phys
2023: Sana Biotechnology will lay off 29% of workforce
2023: Sana lays off staff as cell therapy biotech awaits first clinical data
2024: Sana Biotechnology: Finally Rewarding Investors, But Not Sufficiently Derisked_ seekingalpha.com
2024: Sana Biotechnology: Now In Overbought Territory
2024: Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies_ seekingalpha.com
2024: Sana Biotechnology: The Story Becomes Murkier
2024: Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)_ seekingalpha.com
2024: Sana Biotechnology's SWOT analysis: cell therapy stock faces pivotal year ahead
2024: Sana to lay off staff, deepen autoimmune focus in latest retrenchment
2024: Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
2025: Crispr Offers New Hope for Treating Diabetes
2025: Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued
2025: Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
2025: Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment
2026: Sana Biotechnology and Mayo Clinic Announce Strategic
Jumps
*Key People: Sana Biotech
Finance & Acquisitions: Sana Biotechnology